title: Prognostic factors of patients with thymoma.
abstract: OBJECTIVE
  To analyze the prognostic factors influencing the survival of patients with thymoma, clinical characteristics, treatment modalities and survival of patients were evaluated. The efficacy of chemotherapy was also determined.
  
  
  METHODS
  Retrospective study was done on one hundred patients whose diagnosis was confirmed pathologically at Seoul National University Hospital from 1981 to 1994. The staging was carried out according to the Masaoka system. Survival rate was calculated by the Kaplan-Meier method and prognostic factors were analyzed by a multivariate analysis (Weibull model).
  
  
  RESULTS
  The stage of 100 patients was as follows: Stage I-50, II-6, III-27, IV A-10, IV B-7. The overall survival rates at 5 and 10 years after diagnosis were 73.1% and 58.7%, respectively. The 5-year survival differences, according to various prognostic factors, were as follows: 1) Stage: I-92.8%, II-100%, III-71.6%, IVA-25.9% and IVB-32.9% (p = 0.0029). 2) Age: < 60 years-79.5% and > or = 60 years-41.5% (p = 0.0489). 3) Extent of resection: Total patients: complete resection-87.6% and incomplete resection-50.5% (p > 0.05) Stage III: complete resection-66.7% and incomplete resection-75.5% (p > 0.05) 4) Myasthenia gravis: present-71.6% and absent-74.9% (p > 0.05) Seventeen patients were treated with a combination chemotherapy of Cyclophosphamide, Adriamycin and cisplatin(CAP). Two complete responses and seven partial responses (overall response rate of 53%) were observed with a median response duration of fourteen months. Combination chemotherapy with CAP was effective.
  
  
  CONCLUSIONS
  Stage and age were the independent prognostic factors in patients with thymoma. However, the presence of myasthenia gravis or the extent of resection in stage III patients was not associated with the survival time.
authors.affiliation: Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: W S
authors.initials: WS
authors.lastname: Lee
authors.forename: D S
authors.initials: DS
authors.lastname: Heo
authors.forename: Y J
authors.initials: YJ
authors.lastname: Bang
authors.forename: K S
authors.initials: KS
authors.lastname: Lee
authors.forename: J S
authors.initials: JS
authors.lastname: Ahn
authors.forename: C W
authors.initials: CW
authors.lastname: Jung
authors.forename: S K
authors.initials: SK
authors.lastname: Han
authors.forename: S W
authors.initials: SW
authors.lastname: Sung
authors.forename: J H
authors.initials: JH
authors.lastname: Kim
authors.forename: Y S
authors.initials: YS
authors.lastname: Shim
authors.forename: C I
authors.initials: CI
authors.lastname: Park
authors.forename: N K
authors.initials: NK
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013945:Thymoma / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D013953:Thymus Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*